These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24460291)

  • 1. MCPH1 Protein Expression in Normal and Neoplastic Lung Tissues.
    Zhang J; Wu XB; Fan JJ; Mai L; Cai W; Li D; Yuan CF; Bu YQ; Song FZ
    Asian Pac J Cancer Prev; 2013; 14(12):7295-300. PubMed ID: 24460291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
    Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
    World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues.
    Zhang XL; Dang YW; Li P; Rong MH; Hou XX; Luo DZ; Chen G
    Asian Pac J Cancer Prev; 2014; 15(24):10591-6. PubMed ID: 25605144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
    Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
    Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of inflammasomes in lung cancer cell lines and tissues.
    Kong H; Wang Y; Zeng X; Wang Z; Wang H; Xie W
    Tumour Biol; 2015 Sep; 36(10):7501-13. PubMed ID: 25910707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
    Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
    Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
    J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.
    Gürel D; Kargı A; Karaman I; Onen A; Unlü M
    Pathol Oncol Res; 2012 Apr; 18(2):153-60. PubMed ID: 21681600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FBXO25 promotes cell proliferation, invasion, and migration of NSCLC.
    Jiang GY; Zhang XP; Wang L; Lin XY; Yu JH; Wang EH; Zhang Y
    Tumour Biol; 2016 Oct; 37(10):14311-14319. PubMed ID: 27596142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
    Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
    J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
    Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
    Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer.
    Fan C; Yu J; Liu Y; Xu H; Wang E
    Pathol Oncol Res; 2012 Jul; 18(3):549-56. PubMed ID: 20853080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of FOXP3 expression with non-small cell lung cancer.
    Dimitrakopoulos FI; Papadaki H; Antonacopoulou AG; Kottorou A; Gotsis AD; Scopa C; Kalofonos HP; Mouzaki A
    Anticancer Res; 2011 May; 31(5):1677-83. PubMed ID: 21617226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.